BUSINESS
Divi’s Lab: Operating leverage lifts margin profile
While pricing erosion remains a challenge for generic APIs, new opportunities for generic molecules will unfold in FY26. A lot of drug developments held up during COVID-19 are now getting fast-tracked
BUSINESS
Trade war 2.0: How should investors position themselves when volatility is the only constant?
Investors should focus on sectors that have strong earnings visibility with solid policy backdrop
BUSINESS
Navin Fluorine: Ramp-up in speciality strengthens outlook
An uptick in margins was a major surprise in Q3FY25. A strong order book, the pickup in the specialty segment, and guidance for a stable margin augur well for the company
BUSINESS
Agriculture: Sowing the seeds for more reforms
The budget aims at addressing the rural unemployment issue while ensuring sustainable farming
BUSINESS
Ami Organics: CDMO business brightens growth outlook
Apart from the expected growth in the CDMO and pharma businesses, the com-pany expects an uptick in the semiconductor business in FY26.
BUSINESS
Fed rate status quo marks 'wait and watch' as Trump 2.0 begins
Overriding concern over tariffs though key rate determinants appear to be in control
BUSINESS
Dr Agarwal’s Health Care IPO: A business model with vision, but at a pricey valuation
The eye-care service provider has an impressive execution track record, aided by both organic and inorganic initiatives
BUSINESS
Laurus Labs: Operating leverage playing out
In the coming quarters, performance in the areas of animal health, followed by formulations and crop science chemicals, can aid operating leverage
BUSINESS
Dr Reddy’s: Semaglutide opportunity is a key factor to watch
The long-term prospects for the company are evolving with product approvals in China, build-up of consumer healthcare franchise, and a biosimilar pipeline.
BUSINESS
Budget 2025: Agri sector expects more reforms, measures to boost rural income
Last year, the government set a target of bringing 1 crore farmers into natural farming through the National Mission on Natural Farming within two years. We believe more such steps could be in the offing.
BUSINESS
Will it be shock or celebration for Indian equities as Trump 2.0 kicks off?
The US President’s proposed policy steps can have a far-reaching impact on global markets, with the possibility of emerging markets seeing a relief rally
BUSINESS
RIL Q3 FY25: Consumer businesses drive performance, support outlook
Trends such as premiumisation and rising digital adoption will benefit its consumer-facing businesses while investments in clean energy will create a future growth driver
BUSINESS
Himadri Speciality: Valuation remains a sore point
Though the company is gradually diversifying into businesses like lithium-ion batteries and discovering applications for new end-markets, this journey faces gestation period and execution challenges.
BUSINESS
PCBL: Demand softness, inventory de-stocking weigh on the stock
Medium-term growth is likely to be driven by carbon black exports and the growing specialty exposure, though in short run volume off-take will remain soft.
BUSINESS
Laxmi Dental IPO: Can the public issue lend a big smile to investors?
A play on cutting-edge dental products; long-term investors can consider it post the IPO at more reasonable valuations.
BUSINESS
Medanta: Time to check out this healthcare theme
It is a play on the growing importance of regional health hubs in the northern and eastern states.
BUSINESS
Sai Life Sciences: Differentiated CRDMO business model to help during Trump 2.0
Globally, more than 50 percent of the research and development (R&D) spending is done in nine select pharma hubs, and, hence, it is rewarding to have a presence in these locations.
BUSINESS
Divis Lab: GLP-1 opportunity to unfold in the medium term
Global sales from these drugs in Q3 CY2024 were a staggering $11.2 billion. Street estimates for GLP 1 drugs sales for anti-diabetic and/or obesity control are upwards of $150 billion in 2030.
BUSINESS
Senores IPO: A B2B play in pharma generics
Senores has an interesting business model, focusing on generic product identification and development. For the commercialisation and marketing of those products, it has tied up with large generic players.
BUSINESS
Fed cuts rate but turns hawkish in view of inflation uncertainty
As global trade dynamics are hazy and private capex is fragile, investors should eye bottom-up opportunities in capex recovery and policy supported sectors
BUSINESS
Vijaya Diagnostic Centre: Early success from new geographies reassuring
The company continues to expand beyond its legacy markets — Andhra and Tel-angana — to Pune, Gurugram, and Kolkata
BUSINESS
Sagility: A steady play on US healthcare efficiency initiatives
A defensive bet on the US healthcare spending and upcoming efficiency initiatives
BUSINESS
Sai Life IPO: A pricey proxy for pharma research, development opportunity
More than 50 percent of the global R&D spending is done in nine select pharma hubs, and, hence, it is rewarding to have a presence in these locations
BUSINESS
Should one avoid the FMCG sector now?
The early warning on growth and profit shortfall from Godrej Consumer adds to sectoral concerns
